Pacific Biosciences Of California (PACB) Free Cash Flow Growth (5y) (2015 - 2026)
Pacific Biosciences Of California (PACB) Free Cash Flow Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.46 Bn | 193.86 Bn | 7.27 Bn |
| 2 | Stryker | 127.41 Bn | 123.93 Bn | 4.50 Bn |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.95 Bn | 47.69 Bn | 1.35 Bn |
| 6 | Dexcom | 34.30 Bn | 32.35 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.35 Bn | 23.02 Bn | 4.55 Bn |
| 9 | Steris | 23.04 Bn | 22.55 Bn | 684.20 Mn |
| 10 | Pacific Biosciences Of California | 394.53 Mn | 157.66 Mn | 12.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.53% |
| Mar 31, 2026 | -15.22% |
| Dec 31, 2025 | -6.82% |
| Sep 30, 2025 | -0.30% |
| Jun 30, 2025 | -4.42% |
| Mar 31, 2025 | -21.10% |
| Dec 31, 2024 | -11.99% |
| Sep 30, 2024 | -19.82% |
| Jun 30, 2024 | -25.13% |
| Mar 31, 2024 | -24.53% |
| Dec 31, 2023 | -25.63% |
| Sep 30, 2023 | -35.84% |
| Jun 30, 2023 | -22.66% |
| Mar 31, 2023 | -38.78% |
| Dec 31, 2022 | -25.23% |
| Sep 30, 2022 | -26.09% |
| Jun 30, 2022 | -31.77% |
| Mar 31, 2022 | -33.71% |
| Dec 31, 2021 | -17.31% |
| Jun 30, 2021 | 4.44% |